<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308604</url>
  </required_header>
  <id_info>
    <org_study_id>2016-005127-83</org_study_id>
    <secondary_id>2016/2508</secondary_id>
    <nct_id>NCT03308604</nct_id>
  </id_info>
  <brief_title>AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy</brief_title>
  <acronym>NANOCOL</acronym>
  <official_title>Phase I Study of AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 clinical trial evaluating the safety, tolerability of escalating doses of&#xD;
      AGuIX-NP in combination with radiation and cisplatin in patients with locally advanced&#xD;
      cervical cancer. Dose escalation will be conducted using the modified toxicity probability&#xD;
      interval (mTPI) method.&#xD;
&#xD;
      Three dose levels of intravenous AGuIX nanoparticles will be explored: 20mg/kg (level -1), 30&#xD;
      mg/kg (level 1) and 50 mg/kg (level 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a phase 1 clinical trial evaluating the safety, tolerability of escalating doses of AGuIX-NP in combination with radiation and cisplatin in patients with locally advanced cervical cancer. Dose escalation will be conducted using the modified toxicity probability interval (mTPI) method. Three dose levels of intravenous AGuIX nanoparticles will be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Day 84 after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Day 84 after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with locally advanced cervical cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polysiloxane Gd-Chelates based nanoparticles (AGuIX)</intervention_name>
    <description>Three intravenous injections of AGuIX will be delivered.&#xD;
The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.&#xD;
Irradiation will be performed after the second MRI.&#xD;
The second injection will be followed by an MRI 4 hours later.&#xD;
The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.&#xD;
Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg.</description>
    <arm_group_label>Patients with locally advanced cervical cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiotherapy (EBRT)</intervention_name>
    <description>to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases</description>
    <arm_group_label>Patients with locally advanced cervical cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Uterovaginal brachytherapy</intervention_name>
    <description>15 Gy (maximal interval between EBRT and brachytherapy: 14 days).</description>
    <arm_group_label>Patients with locally advanced cervical cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy (cisplatin)</intervention_name>
    <description>Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).</description>
    <arm_group_label>Patients with locally advanced cervical cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed cancer of the uterine cervix: squamous cell&#xD;
             carcinoma or adenocarcinoma stage IB2-IVA according to the International Federation of&#xD;
             Gynecology and Obstetrics classification, regardless of the pelvic lymph node stage.&#xD;
             No evidence of metastatic disease. Primary staging should include: clinical&#xD;
             examination, Pelvic MRI and 18-FDG PET. A coelioscopic para-aortic lymph node staging&#xD;
             should be done in patients without para-aortic lymph node uptake to guide radiotherapy&#xD;
             fields in the situation of pelvic lymph node metastases. If there is no pelvic lymph&#xD;
             node metastases, para-aortic lymph node dissection is optional.&#xD;
&#xD;
          2. ECOG performance status 0-1.&#xD;
&#xD;
          3. Age between 18 - 70 years.&#xD;
&#xD;
          4. Neutrophils &gt; 2000/mm^3.&#xD;
&#xD;
          5. Hemoglobin &gt; 9 g/L after transfusion if necessary.&#xD;
&#xD;
          6. Platelets &gt; 100,000/mm^3.&#xD;
&#xD;
          7. Creatinine &lt; 1.5 upper limit of normal or calculated creatinine clearance&#xD;
             (Cockcroft-Gault Formula) ≥ 60 mL/min.&#xD;
&#xD;
          8. Liver function (GOT, GPT, alkaline phosphatase and bilirubin) &lt; 1.5 upper limit of&#xD;
             normal.&#xD;
&#xD;
          9. Cardiovascular: no clinically relevant cardiovascular disease, no congestive heart&#xD;
             failure, no symptomatic coronary artery disease, no poorly controlled cardiac&#xD;
             arrhythmia, no myocardial infarction within the past year.&#xD;
&#xD;
         10. Gastrointestinal: no active inflammatory bowel disease, no lack of physical integrity&#xD;
             of the upper gastrointestinal tract, no malabsorption syndrome.&#xD;
&#xD;
         11. Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to initiation of treatment.&#xD;
&#xD;
         12. Proteinuria &lt; 2 g/L (200mg/dL) and creatinine clearance ≥ 60 mL/min.&#xD;
&#xD;
         13. Signed informed consent after informing the patient.&#xD;
&#xD;
         14. Patient affiliated to a social security regimen or beneficiary of the same.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other histological types of cervical cancer than those listed in the inclusion&#xD;
             criteria or stage IVB.&#xD;
&#xD;
          2. History of cancer other than basal cell carcinoma within five past years.&#xD;
&#xD;
          3. Prior treatment with radiotherapy, chemotherapy, targeted therapy or immune therapy&#xD;
             for cervical cancer or for any cancer within five past years.&#xD;
&#xD;
          4. Prior pelvic radiotherapy or prior surgical treatment for cervical cancer (excluding&#xD;
             diagnostic conisation).&#xD;
&#xD;
          5. Pregnancy or breastfeeding.&#xD;
&#xD;
          6. Obesity (Body Mass Index &gt; 30).&#xD;
&#xD;
          7. History of prior or current psychiatric illness.&#xD;
&#xD;
          8. Nephropathy, regardless of the grade.&#xD;
&#xD;
          9. Peripheral neuropathy ≥ grade 2.&#xD;
&#xD;
         10. Patients with pre-existing hearing impairments.&#xD;
&#xD;
         11. Active infection or other serious underlying pathology that could prevent the patient&#xD;
             from receiving the treatment (especially liver or heart conditions).&#xD;
&#xD;
         12. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus&#xD;
             ribonucleic acid (HCV antibody) indicating acute or chronic infection.&#xD;
&#xD;
         13. Positive test for human immunodeficiency virus (HIV) or known acquired&#xD;
             immunodeficiency syndrome (AIDS).&#xD;
&#xD;
         14. Inclusion in another clinical trial protocol with an experimental molecule (during&#xD;
             this study or within 5 years prior to enrollment).&#xD;
&#xD;
         15. Unable to undergo the follow-up required by study for geographical, social or&#xD;
             psychological reasons.&#xD;
&#xD;
         16. Contra-indication for Magnetic Resonance Imaging enhanced with gadolinium and/or any&#xD;
             contra-indication to the use of cisplatin.&#xD;
&#xD;
         17. History of allergic reaction to cisplatin or other platinum containing compounds.&#xD;
&#xD;
         18. Concurrent administration of yellow fever vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gynecologic Cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyrus CHARGARI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cyrus CHARGARI, MD</last_name>
    <phone>+33 (0) 1 42 11 42 11</phone>
    <phone_ext>33 65</phone_ext>
    <email>cyrus.chargari@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu TEXIER</last_name>
    <phone>+33 (0) 1 42 11 62 52</phone>
    <email>matthieu.texier@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <state>Rhône</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ionela CARAIVAN, MD</last_name>
      <phone>+33 (0) 4 78 86 42 60</phone>
      <email>ionela.caraivan@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Ionela CARAIVAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrus CHARGARI, MD</last_name>
      <phone>+33 (0) 1 42 11 42 11</phone>
      <phone_ext>33 65</phone_ext>
      <email>cyrus.chargari@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu TEXIER</last_name>
      <phone>+33 (0) 1 42 11 62 52</phone>
      <email>matthieu.texier@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cyrus CHARGARI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 9, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

